We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roche is stopping its phase 3 trial of tominersen, its investigational drug to treat Huntington’s disease, a rare neurodegenerative condition for which there is no known cure. Read More
Regeneron Pharmaceuticals’ and Roche’s antibody cocktail, REGEN-COV (casirivimab/imdevimab), reduced the risk of hospitalization or death by 70 percent in high-risk nonhospitalized COVID-19 patients in a late-stage trial, the companies have said. Read More
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) plans to resume in-person inspections of drug facilities starting March 29 but it will adopt a hybrid approach that allows for both remote and on-site elements. Read More
Roche’s blockbuster oncology drug Tecentriq (atezolizumab) met its primary endpoint of disease-free survival in its phase 3 lung cancer study evaluating the drug as an adjuvant therapy, according to an interim analysis. Read More
The European Medicines Agency (EMA) has advised against the use of Merck’s anti-parasitic drug Stromectol (ivermectin) for the prevention and treatment of COVID-19. Read More
As the EU’s COVID-19 vaccine supply woes intensify, the 27-member bloc is signaling it could make good on its threat to halt exports of vaccine doses to the UK as soon as this week. Read More
The FDA has promised transparency as it implements data and technology modernization initiatives in its latest discussions with industry ahead of the next reauthorization of the Prescription Drug User Fee Act (PDUFA). Read More
PhRMA is still battling a final rule from the Trump Administration era to allow in pharmaceuticals from Canada and has filed a citizen’s petition asking the FDA to block New Mexico’s plan for importing drugs. Read More